Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02752074 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
A Phase 3 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 706
- Enrollment target
NCT02752074 is a Phase 3 study that has completed, run by Incyte Corporation. The registered enrollment target is 706 participants.
The verdict
NCT02752074, a Phase 3 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 706 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in participants with unresectable or metastatic melanoma
Interventions
- DRUG pembrolizumab + epacadostat
- DRUG pembrolizumab + placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 706 participants |
| Start Date | 2016-06-21 |
| Est. Completion | 2019-08-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02752074
The ClinicalTrials.gov registry entry for NCT02752074 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 706 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pembrolizumab + epacadostat is the first listed.
NCT02752074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02752074 about?
NCT02752074 is a clinical study titled "A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)". The purpose of the study is to assess the efficacy, safety, and tolerability when combining pembrolizumab with epacadostat or placebo in participants with unresectable or metastatic melanoma
What is the current status of trial NCT02752074?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 706 participants. The study started on 2016-06-21. Estimated completion is 2019-08-16.
What interventions are being tested in trial NCT02752074?
The interventions under investigation include: pembrolizumab + epacadostat (DRUG), pembrolizumab + placebo (DRUG).
Who is sponsoring clinical trial NCT02752074?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.